Cytokinetics Stock News

Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D Read more

SOUTH SAN FRANCISCO, Calif., July 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $450.0 million aggregate Read more

SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market and other cond Read more

Meeting Currently Scheduled for December 13, 2022 Meeting Currently Scheduled for December 13, 2022 Read more

Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term Read more

Recent Company Submission in Response to FDA Request Extends PDUFA Date Recent Company Submission in Response to FDA Request Extends PDUFA Date Read more

Managed Access Program for People Who Have Completed Prior Cytokinetics ALS Trials to Begin in 2H 2022 Managed Access Program for People Who Have Completed Prior Cytokinetics ALS Trials to Begin in 2H Read more

Echocardiographic Data Show Treatment with Aficamten for 10 Weeks Results In Improved Cardiac Structure, Myocardial Relaxation and Mitral Valve Mechanics Read more

Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 0 0 0 Last 30 Read more

SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from a new analysis from REDWOOD-HCM (Randomized Eval Read more

Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30 Read more

Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class, Symptoms, and Biomarkers Read more

FDA Plans to Convene Advisory Committee Meeting FDA Plans to Convene Advisory Committee Meeting Read more

Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading. Susquehanna cut Taboola.com Ltd. (NASDAQ: TBLA) price target f Read more

Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? Read more